A range of posters presented at the 2023 American Thoracic Society (ATS) International Conference highlighted a plethora of risk factors for pulmonary conditions in adulthood outside of tobacco smoking history.
Pulmonary conditions such as chronic obstructive pulmonary disease (COPD) and lung cancer share a common risk factor in tobacco smoking, but a variety of known and potentially impactful factors may also come into play, as shown by research presented at the 2023 American Thoracic Society International Conference.
A range of posters presented at the conference, which took place in Washington, DC, highlighted a plethora of risk factors for pulmonary conditions outside of smoking history. A pair of posters explored asthma status and COPD exacerbations in adults.
There is limited research on pulmonary disease status in elderly adults who have a history of asthma in childhood, according to one poster presented at the session.1
In a 60-year follow-up study of children with a history of severe childhood asthma, researchers assessed disease characteristics via questionnaires and measurements of blood samples, spirometry, fractional exhaled nitric oxide, bronchodilator reversibility, bronchial provocation with mannitol, and static lung volumes.
In a cohort of 1401 individuals in Denmark with severe childhood asthma, 169 had been examined at the time of the analysis. About half were never-smokers, and only 7.1% reported 1 exacerbation in the past 12 months. In the assessed cohort, 147 (86.9%) still had asthma, and 24 of these had concomitant COPD. Compared with patients who had asthma remission in adulthood, those with asthma had worse lung measurements.
Overall, the study found that 1 in 10 patients in the cohort had asthma remission, and 1 in every 3 had persistent airflow limitations. This suggests that severe childhood asthma is a risk factor for severe, possibly debilitating lung disease in elderly adults.
Another poster explored hospitalization outcomes in a cohort of patients with asthma-COPD overlap (ACO) syndrome compared with individuals with only asthma or COPD.2
“Recently, ACO, a phenotype with clinical features of both diseases, has been associated with increased exacerbation frequency and healthcare utilization in comparison to either disease alone,” the authors wrote. But hospital-based outcomes have not been described in research to the authors’ knowledge.
The researchers compared outcomes of index admissions and 30-day readmissions among 2,522,013 patients with asthma (n = 668,867), COPD (n = 1,732,946), or ACO (n = 120,200), as well as baseline patient characteristics and demographic data.
ACO was associated with higher rates of comorbidities at baseline, although patients with ACO were younger on average than those with COPD alone (63 years vs 69 years). Despite being younger, patients with ACO had higher rates of respiratory failure, increased hospital length of stay, and higher costs during index admissions, but not a significantly higher risk of readmissions.
Overall, ACO was associated with longer hospital stays and higher care costs vs asthma or COPD alone, but not increased mortality or readmission risk. The findings show a differential burden of ACO vs asthma or COPD alone.
References
1. Savran O, Bonnelykke K, Ulrik CS. Characteristics of adults with a history of severe childhood asthma - a cohort study with a 60-year follow-up. Abstract presented at: American Thoracic Society International Conference; May 20-24, 2023; Washington, DC. Accessed May 24, 2023.
https://cattendee.abstractsonline.com/meeting/10703/Presentation/7735
2. Sleiman J, Attaway A, Zein J, Rowlands W. Analysis of hospitalization outcomes in patients with asthma-COPD overlap syndrome. Abstract presented at: American Thoracic Society International Conference; May 20-24, 2023; Washington, DC. Accessed May 24, 2023. https://cattendee.abstractsonline.com/meeting/10703/Presentation/7737
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces at AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More